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Progress Report  
Scientific Goals. A number of proteases (protein hydrolyzing enzymes) 
have been shown to be involved in diseases such as pulmonary emphysema and 
arthritis which involve tissue destruction. The goal of this research was 
to design and synthesize specific and effective protease inhibitors. The 
inhibitors should be invaluable in the study of the normal biological function 
and the role of proteases in disease. In addition, synthetic protease inhibitors' 
should find use in the clinical treatment of a variety of diseases including 
pulmonary emphysema, rheumatoid arthritis, certain types of tumors and viral 
infections. 
Significance. Proteases are involved in the regulation of many important 
biological processes. Some of the better known examples are blood coagulation, 
fibrinolysis, complement activation, fertilization, protein processing, digestion 
and phagocytosis. Some of these processes involve cascades of proteolytic events. 
For example, in the resting state, both the coagulation and complement systems 
are composed of a number of plasma zymogens of proteases. Upon receipt of an 
appropriate signal some of these•zymogens are converted into active proteases 
which in turn activate other zymogens producing a cascade of enzymatic reactions. 
The initial signal in the coagulation system is the formation of new surfaces 
at the site of a wound and the end result is formation of the fibrin clot. In 
the complement system, initial formation of antigen-antibody complexes leads to 
the lysis of foreign cells. In both cases, the cascade of proteolytic events 
gives a system for prompt amplification and control of the initial signal. 
Proteases and Disease. Since a major component of all cells is protein, 
proteases could be very destructive if they were not carefully controlled or 
compartmentalized. The potential seriousness of uncontrolled proteolysis can 
be recognized by the fact that ca. 10% of the proteins by weight found in human 
plasma are protease inhibitors. In addition to the plasma inhibitors, there 
are other inhibitors which are more localized and have not been as well characterized. 
It is now believed that many diseases result when there is an imbalance between 
speefic proteases and their natural inhibitors. Some examples of proteases 
which have been linked to specific diseases (and the protease involved) are 
emphysema (leukocyte elastase and cathepsin G), arthritis (collagenase), pan-
ceeatits (pancreatic serine proteases), cancer (collagenase, plasminogen 
activator), hypertension (renin and anoiotension converting enzyme), inflammation 
(mast cell proteases) and amyloidosis (elastase). 
Emphysema. Emphysema is one disease where the linkage between proteolysis 
E--1d. the disease is fairly well understood. Pulmonary emphysema is a disease 
cnaracterized by a progressive loss of lung elasticity due to the destruction 
of lung elastin and alveoli. Respiration becomes increasingly difficult and 
death often results. 
The first clue to the involvement of proteases in emphysema was the 
observation by Lauren and Ericksson that individuals who were homozygotes in 
an a l -rotease inhibitor (a l eantitrypsin) deficiency were predisposed to the 
disease. This serum protease inhibitor inhibits a spectrum of proteases in-
culdag elastase and cathepsin G which are found in the granules of human 
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leukocytes. Leukocyte proteases are normally involved in phagocytosis in the 
lung and contribute to the turnover of damaged lung cells and the digestion of 
invading bacteria. In normal individuals a l - PI protects the lung from digestion 
of any of the proteases which may leak from leukocytes. In individuals not so 
protected, proteolysis of lung elastin leads to the development of emphysema. 
The a l -PI of PiZ individuals has a one amino acid substitution (Lys for Glu) 
somewhere in the sequence. As a result, the a -PI of PiZ individuals accumulates 
in the liver and is not exported to the plasma. 
A major predisposing factor for the development of chronic obstructive 
pulmonary disease is cigarette smoking. It is now believed that a l -PI is 
inactivated either directly by oxidants in the smoke or by myeloperoxidase 
which is released from leukocytes. 
Cigarette smoke decreases the a l - PI activity in rat lung and produces a 
functional deficiency of protease inhibitors in the lower respiratory tract of 
humans. It is quite reasonable to assume that this is due to the oxidation of 
the essential methionine residue in a l -PI. Thus, chemical modification of a l - PI 
by oxidation of a methionine residue to a methionine sulfoxide residue by some 
component of cigarette smoke or by myeloperoxidase which is released by cigarette 
smoke, results in inactivation of this essential protease inhibitor. The resulting 
imbalance of proteases and protease inhibitors in the lung then results in the 
development of emphysema. 
Synthetic Protease Inhibitors. Our research on synthetic protease inhibitors 
has been focused on two of the four classes of proteases. One major goal was to 
develop specific and effective inhibitors for the serine proteases elastase and 
cathepsin G from human clinical treatment of pulmonary emphysema. The second 
major goal was to develop new types of inhibitors for metalioprotease&. 	Initially 
we utilized thermolysin as a model system for the development of new classes of 
inhibitors. We.then tried to extend these inhibitors to other important metallo-
proteases. 
Studies with Human Leukocyte Enzymes. Proteolysis by enzymes released from 
human PM-  leukocytes are involved in several major diseases which involve tissue 
destruction. In the case of pulmonary emphysema, elastase seems to be principally 
responsible for lung damage with cathepsin G and other protease carrying out 
secondary digestions. We have previously synthesized a number of specific peptide 
aloroffethyl ketone inhibitors of both human leukocyte elastase and cathepsin G. 
The best elastase inhibitor is Meg-Suc-Ala-Ala-Pro-ValCH 2 C1 and the best cathepsin 
O inhibitor is Z-Gly-Leu-Phe-CH 2 C1. 
One concern that is often expressed about peptide chloromethyl ketones, is 
ther ability to alkylate a varie4 of nucleophiles in proteins. This is thought 
to be a major limitation to the use of chloromethyl ketones in physiological 
situe.tions. In order to evaluate the significance of side reactions with other 
nuceophiles, the rate of reaction of the thiol glutathione with Me0-Suc-Ala-Ala-
Pro-ValCH 2 C1 was-measured and found to be quite slow. This inhibitor would 
discriminate in favor of leukocyte glutathione by a factor of 1770 if the con-
centrations were equivalent. Thus, Me0-Suc-Ala-Ala-Pro-Va1CH 2 C1 appears to be 
a highly reactive and selective elastase inhibitor for use in physiological 
situations. 
Animal Studies. Three research groups have studied the effect of synthetic 
elastase inhibitors in animal models of emphysema. We collaborated with and 
supplied inhibitors to all three groups. In each case, elastase was used to 
induce emphysema in the lungs of hamsters or mice. Dr. J. Kleinerman showed 
that Ac-Ala-Ala-Pro-AlaCH2 C1 had significant anti-elastase activity in vivo  
(hamsters), markedly decreased the extent of elastase-induced emphysema, and 
produced no adverse toxic effects during the period covered by the study 
(120 days). Dr. P. Stone (Boston U.) has obtained similar results using Suc-
Ala-Ala-Pro-Va1CH2 C1. Dr. A. Janoff (Stony Brook) has shown that Me0-Suc-Ala-
Ala-Pro-Va1CH2 C1 is orally active in preventing elastase induced emphysema in 
mice. 
We are continuing to collaborate with the research groups carrying out 
animal studies with elastase inhibitors. We completed the synthesis of 9 g 
of Ac-Ala-Ala-Pro-AlaCH 2 C1 for Dr. Kleinerman. He is currently studying the 
effects of this inhibitor on the progression of emphysema in hamsters. During 
a two year study, the inhibitor will be given daily subsequent to induction of 
emphysema in the animals. 
At present many questions remain concerning the toxicity, immunogenicity 
and carcinogenicity of peptide chloromethyl ketones. However, these inhibitors 
have already been useful in showing that elastase inhibitors can be used for 
the in vivo treatment of emphysema. 
Sulfonyl Fluorides. Sulfonyl fluorides inhibit serine proteases by reaction 
with the active site serine residue. Previously we investigated the rates of 
inhibition of elastase and cathepsin G by a variety of sulfonyl fluorides and 
found relatively little selectively or reactivity. However, we recently dis-
covered that the introduction of fluoroacyl groups into the sulfonyl fluoride 
structure gives inhibitors with considerable reactivity and selectivity. 
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The values listed under each compound are inhibition rates (k, s /[1] at pH 7.5). 
These are the best elastase inhibitors of a large number of u ' sulfonyl fluorides 
which we have synthesized and tested. All three are very effective inhibitors of 
human leukocyte elastase and the latter two are quite specific. SUlfonyl fluorides 
without the fluoroalkyl groups or the meta- and para- isomers are unreactive. 
Sulfonyl fluorides are not generally considered to be toxic and these inhibitors 
may find utility in the treatment of human disease. 





Other Inhibitor Structures. Based on our work with sulfonyl fluoride 
inhibitors of H1 elastase, we reasoned that other structures containing 
fluoroacyl groups might be elastase inhibitors. In particular, the aldehyde 
1 might be a transition state analog and form a hemiacetal with the enzyme. 
The nitrophenyl ester 2 and the thiobenzyl ester 3 might be substrates or 
specifically acylate the enzyme and form stable acyl enzyme derivatives. 
Thus we decided to synthesize these compounds. 
All of the compounds reacted with elastase, although not necessarily in 
the way that we had expected. The aldehyde was a weak inhibitor with a K T of 
18 mM. The nitrophenyl ester was fairly unstable in aqueous medium, but did 
not acylate elastase. However the acyl enzyme was unstable and hydrolyzed 
fairly rapidly. The thiobenzyl ester in contrast was not a HL elastase sub-
strate, but instead was a potent inhibitor with a K of 1 1M. Needless to 
say, we synthesized a number of other thioester derivatives related to 3 and 
discovered a fair number of potent inhibitors for elastase and chymotrypsin 
which I will not describe (they are discussed in Teshima et al., 1982). 
HETEROCYCLIC INHIBITORS. During the synthesis of thioesters of N-acyl-
anthranilic acid related to 3, we became aware of the fact that cyclization to 
2-substituted-4H-3,1-Benzoxazin-4-ones (4) could take place. 
We synthesized 4 and found it to be a potent elastase inhibitor. We then 
decided to synthesize other deri\vives and found a number of benzoxazinones 
with K T values in the 10-6 to 10 	M range. The best HL elastase inhibitor 
was tb1 heptafluoropropyl derivative (4, R=CF 2CF2CF 3 ) which had a K 1 of 92 nM. 
Toe reversible HL elastase inibitors which we discovered are significantly 
better than most of the previously reported reversible 'inhibitors for this enzyme. 
In fact the K T values observed with the benzoxaznones are almost 10 fold lower 
than tnose re sorted for transition analogs sucq as Ac-Pro-Ala-Pro-NHOH(CH 2 )CHO 
the related enzyme, PP elastase (K T -MO % Thompson, 1973). Our b6st 
cathepsin 0 inhibitor (4, R=CF 2CF 2CF3 ) was equally as potent as the peptide 
aldehyde chymostatin (a transition state inhibitor). 
We believe the fluoroalkyl or alkyl substituents on the various 
heterocyclic ring systems are interacting with the S 1 pocket of HL elastase. 
With the benzoxazinones, the 2-propyl derivative has a lower K 1 than either 
the benzyl or methyl derivative which is consistent with the substrate 
specificity of this enzyme. In all cases, substitution of a fluoroalkyl 
group for an alkyl group decreased the KT value. In most cases, a one-to-two 
order of magnitude change was observed. 'Again this is consistent with binding 
in the hydrophobic S 1 pocket. 
f 
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Ci —14 • Schematic Model for the 
binding of 2-heptafluoropropyl-
4H-3,l-Benzoxazine-4-one to the 
active site of HL elastase 
During the course of this investigation we noticed that there seemed to 
be a correlation between the inhibitory activity of the various inhibitors and 
their carbonyl stretching frequencies in the infrared. We then made a plot of 
pK, versus carbonyl stretching frequency for 26 different compounds. An 
e)eelint correlation was observed with the best inhibitors having the higher 
carbonyl stretching frequencies. If all 26 compounds were included, a corre-
lation coefficient of 0.84 was obtained in a least square fit of the data. 
c=wever, if only trifluoroacetyl or truoromethyl derivatives were included, 
the correlation coefficient increased to 0.89. The inhibitors studied ranged 
in 	values from 10 -2 ,to 10 - and had carbonyl stretching frequencies that 
had 6. range of 120 cm- '. Thus the correlation between pK I and the carbonyl 
stretching frequency is astonishingly good. 
.ee strong correlation betweee the carbonyl stretching frequency and pK I 
proT;des strong support for the hyothesis that all of the inhibitors are 
ittereeting with elastase at 	nlreey1 groups. As the carbonyl stretching 
frequency increases, binding of tbe inhibitors to the enzyme increases. Carbonyl 
compounds become more polarized and more susceptible to nucleophic attack as the 
carbonyl stretching frequency incases. We propose that an electrostatic 
ieterna.cton is occurring between the charge relay system of the serine protease 
aed the carbonyl group of the inhibitors (5 to 6). If the serine oxygen is 
interecting with the carbonyl carbon as shown in 6, it is not difficult to 
le:aoine the formation of a tetrahedral intermediate if bonding occurred between 
t i e carbonyl carbon and the Serine y-oxygen (7). Such tetrahedral complexes 
are formed upon interaction of peptide aldehydes with serine proteases. How-
ever if a tetrahedral complex is formed between any of our inhibitors and 
elastase, there must be forces which restrain further reaction to form an 
acyl enzyme, followed by hydrolysis. With the sole exception of the nitro-
phenyl ester 2, none of the inhibitors were hydrolyzed by any of the enzymes 
investigated. Since formation of a tetrahedral intermediate 7 without 
continuation on the reaction pathway seems rather improbably to us for many 
of the compounds examined, we prefer an inhibition model which simply involves 
interaction of a partially polarized carbonyl group with a partically polarized 
charge relay system. 
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In conclusion we have developed a novel series of potent heterocyclic 
inhibitors for HL elastase and other serine proteases. Some of the inhibitors 
are highly specific for HL elastase. The inhibitors can be considered in one 
sense to be transition state analogs. Also we have confirmed the observation 
with sulfonyl fluorides that it i feasibe to develop small non-peptide mole-
cules which are effective and specific inhibitors for HL elastase. 
This work has been completely described in a recent publication (Teshima 
et. al., 1982). 
Metalloproteases. A number 	metalloproteases are involved in diseases 
which involve connective tissue destruction. Collagenase has been found in 
rheumatoid synovium and has been implicated in the destruction of joints in 
rheumatoid arthritis. Collagenase may also be involved in periodontal disease, 
corneal ulceration, and several tuner diseases. Invasive tumors have been shown 
to secrete collagenase and the ablity of this enzyme to attack connective tissue 
may allow such tumors to expand ieto the surrounding tissue. 
long-term plan for the Oevelopent of collagenase inhibitors was to 
u se t'rairmolysin as a model system, This zinc metalioprotease is more readily 
eva -Hajile than collagenase and woeld bind smaller peptides. This allowed us 
to investigate a number of different inhibitors (both reversible and irreversible) 
for thermolysin (Rasnick and Powers, 1978; Nishino and Powers, 1979 reprints 
previously supplied). The best reversible inhibitors are phosphoramidates, 
nydroxamic acids and thiols. The hydroxamic acid NONH-Bzm-Ala-Gly-NH 2 (Bzm= 
-COCH(CH 9 C,;,H E )C0-) is an excellent inhibitor of thermolysin (K I 	0.7 pM) 
and has beWattached to agaroe and used in the affinity purification of 
thermolysin. A number of irreversible thermolysin inhibitors such as C1CH 2 CON 
(OH)CH(CH9CH(CH2CH(CH3 )
2 2  CO,CH, were synthesized. The site of the reaction was ,  
9 
Pseudomonas aeruginosa Elastase. Once we had developed specific inhibitors 
for thermolysin, we began to extend these inhibitors to other metalloproteases. 
One of our first targets was the elastase from P. aeruginosa since it's substrate 
specificity was quite similar to that of thermolysin. Pseudomonas aeruginosa  
elastase in an infectious organism which is resistant to many antibiotics. This 
organism cause hemorrhagic pneumonia in mink and corneal ulcers in man. Many 
strains of P. aeruginosa produce an elastase. Those strains with elastase have 
been shown to be more pathogenic than those without. The elastase is likely the 
factor responsible for the destruction of corneal tissue and hemorrages of the 
lung observed in P. aeruginosa infections. 
We synthesized a new substrate and a number of inhibitors for P. aeruginosa  
elastase (Nishino and Powers, 1980). The substrate Abz-Ala-Gly-Leu-Ala-Nba 
(Abz, 2-aminobenzoyl; Nba, NHCH 9 H A N0 9 ) contains a fluorescent group (Abz) and a 
quenching group (Nba). Cleavagb of 'the peptide by elastase results in a 6- to 
7-fold increase in fluorescence. A sensitive rate assay utilizing this substrate 
was developed and used to study inhibitors. Some of the best reversible inhibitors 
are listed below: 
HONHCOCH(CH 2 C6H 5 )CO-Ala-Gly-NH 2 	K = 0.044 pM 
HSCH2CH(CH 2 C 6H 5 )CO-Ala-Gly-NH 2 	 0.064 0 
CHO-HOLeu-Ala-Gly-NH 2 	 8.0 	pM 
phosphoramidon 	 0.055 pM 
We have proposed that the inhibitors bind to the extended substrate binding 
region of elastase with the inhibitor ligating the active site zinc of the 
enzyme. A moderate irreversible inhibitor was also designed and synthesized. 
Such inhibitors may be of value in the future for the treatment of infections 
due to P. aeruginosa. This work has been reported (Nishino & Powers, 1980). 
The thermolysin and P. aerudosa elastase inhibitors are also effective 
at inhibiting a metalloprotease 	dog pancreatic membranes (Zimmerman et. 
1930). In addition, some of the eopo(.,As inhibit a mouse ascites tumor 
d4eptise (collaborative project witn E. Piltterson, Fox Chase Cancer Center, 
Phi., Pa.). the hydroxamic acid -;etalDproease inhibitors which we have 
developed have been exteheed to 	Jr -igicien:,irf converting enzyme by two 
industrial groups and to aminopepdse 	wi-) other research groups. Finally 
one of our hydroxamic acid thermolysin inhibrs has recently been shown to 
be a potent enkephalinase 
Thus far little progress has boon made toward the development of a 
coflagenase inhibitor. We plan to pursue this problem in the future. 
